Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract reviews the use and effects of various antiandrogens, finding clinical benefits in treating hyperandrogenism in women and improvements in urinary symptoms or cancer management in men, but it reports no new clinical results.

This article provides an endocrine perspective on evaluating and managing hirsutism but reports no new research findings.

This article discusses nutritional contributions to hair health and highlights the need for identifying risk factors for deficiencies but reports no new clinical findings.

This study used a network meta-analysis to compare alopecia areata treatments, finding that intralesional corticosteroids are most effective for mild cases, while diphenylcyclopropenone ranks highest for moderate to severe cases; further research on oral tofacitinib is needed.

This article reviews common skin reactions associated with epidermal growth factor receptor inhibitors and reports no new clinical findings, emphasizing the need for understanding nursing care and oncodermatology.

This review discusses the prognosis and treatment options for hair shaft disorders, finding no studies but suggesting some disorders improve with specific treatments like minoxidil and retinoids, while gentle hair care remains essential.

This review discusses potential treatments for androgen excess in polycystic ovary syndrome and reports no new findings, emphasizing the importance of individualized antiandrogenic management to minimize side effects.

This article reviews the diagnostic criteria and management strategies for polycystic ovary syndrome but reports no new clinical findings; it highlights associated health risks and recommended treatments.

This review discusses various patent articles on microemulsion carriers in drug delivery systems and reports no new empirical findings.

This review discusses the distinctive non-infective skin presentations of HIV infection from a dermatological perspective and reports no new clinical findings.

This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.

This study analyzed social media posts to assess pet toxicosis from topical minoxidil exposure, finding that many pet owners were unaware of its toxicity risks, particularly for cats, and highlighted a significant need for increased educational efforts to prevent such incidents.

This article discusses the challenges of diagnosing and managing polycystic ovarian syndrome and reports no new research findings, emphasizing the need for improved diagnostic criteria and lifestyle intervention to prevent complications.

This review focuses on the clinical presentation and management challenges of menopausal acne and reports no new experimental findings.

This article reviews the complications and health risks associated with polycystic ovary syndrome and reports no new clinical findings.

Hair loss significantly affects quality of life, wet combing is better than visual inspection for finding head lice, many with oral lichen planus have allergies, and wet wraps with steroids quickly improve itchy skin conditions.

This review discusses how menopause and hormone replacement therapy affect skin aging in women but reports no new clinical findings.

This abstract provides a brief introduction to Propecia® (finasteride 1mg) but reports no new research findings.

This article reviews treatment options for androgenetic alopecia and suggests that therapy should be personalized and targeted at various pathophysiological aspects, but reports no new clinical findings.

This review discusses the use of finasteride for androgenetic alopecia and highlights that while it is considered safe, there is concern regarding its sexual side effects, which reverse upon discontinuation.

According to this study, systemic retinoids, specifically oral isotretinoin and acitretin, were more effective than finasteride in stabilizing the frontal hairline in female patients with frontal fibrosing alopecia, achieving treatment goals in over 70% of cases.

In this clinical experience, treating frontal fibrosing alopecia with oral finasteride, hydroxychloroquine, tacrolimus, and excimer laser was associated with optimal results in patients with active inflammation.

This review summarizes recent therapeutic advancements in treating various forms of alopecia, including new applications of oral minoxidil, dutasteride, finasteride, Janus kinase inhibitors, and novel hair transplant techniques, without presenting original research results.

This review discusses treatment options for androgenetic alopecia, with a focus on the better efficacy of oral finasteride and dutasteride over topical minoxidil for male pattern hair loss, but it reports no new clinical results.

This study aimed to develop a new transdermal patch for treating androgenetic alopecia using finasteride, combined with chemical permeation enhancers to improve drug delivery through the skin, but results of pharmacokinetics and pharmacodynamics evaluations are not reported.

Vitiligo may be linked to stopping finasteride.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This systematic review and meta-analysis found that oral minoxidil improved hair loss symptoms in many patients, with significant improvement in 35%, but 27% experienced adverse events, highlighting the need for further research to confirm its safety and efficacy.

This study found that while finasteride effectively improves hair growth in male androgenetic alopecia, it may affect fertility at higher doses, and the evidence on its long-term sexual side effects is inconsistent and requires more rigorous research.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.